Williams V, Qin S, Romano CD, Lewis S, Williams N, Yarr S, Juul KV, Andersson FL. Psychometric evaluation of the Nocturia Sleep Quality Scale based on data from a prospective observational study. J Clin Sleep Med. 2021 Apr 1;17(4):691-701. doi: 10.5664/jcsm.9010
Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med. 2011 Feb 14;171(3):218-25.
Simpkins J, Divine G, Wang M, Holmboe E, Pladevall-Vila M, Williams LK. Improving asthma care through recertification: a cluster randomized trial. Arch Intern Med. 2007 Nov 12;167(20):2240-8.
Pignone M, Earnshaw S, Pletcher MJ, Tice JA. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med. 2007 Feb 12;167(3):290-5.
Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley DJ, Mangel AW. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med. 2001 Jul 23;161(14):1733-40.
Wolfinger RD, Gibson G, Wolfinger ED, Bennett L, Hamadeh H, Bushel P, Afshari C, Paules RS. Assessing gene significance from cDNA microarray expression data via mixed models. J Comput Biol. 2001 Jan 1;8(6):625-37.
Pladevall M, Arana A, Varas-Lorenzo C. Systematic reviews and meta-analyses in ischemic cardiopathy. Cardiovasc Risk Fact. 2000;4:270-81.
Pladevall-Vila M, Arana A, Varas-Lorenzo C. Systematic reviews and meta-analysis on coronary heart disease. (Revisiones sistemáticas y meta-análisis en cardiopatía isquemica). Cardiovasc Risk Fact. 2000;4:270-81.
Bollini P, Garcia Rodriguez LA, Perez GS, Walker AM. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med. 1992 Jun 1;152(6):1289-95.
Jick H, Porter J, Morrison AS, Rothman KJ. Lung cancer in young women. Arch Intern Med. 1979 Jul 1;139(7):745-6.